Estradiol valerate/prasterone enanthate explained

Estradiol valerate/prasterone enanthate (EV/DHEA-E), sold under the brand name Gynodian Depot among others, is an injectable combination medication of estradiol valerate (EV), an estrogen, and prasterone enanthate (-E), an androgen, estrogen, and neurosteroid, which is used in menopausal hormone therapy for women.[1] [2] [3] [4] [5] [6] [7] [8] It is provided in the form of 1 mL ampoules containing 4 mg estradiol valerate and 200 mg prasterone enanthate in an oil solution and is administered by intramuscular injection once every 4 to 6 weeks. EV/DHEA-E reportedly has a duration of about 21 days.[9]

The medication is available in Europe, Latin America, and Egypt.[10] [11] [12] [13] EV/DHEA-E was developed and marketed by Schering, was first described in the literature in 1972, and was introduced for medical use in April 1975.[14] [15] [16]

See also

Notes and References

  1. Web site: Gynodian® Depot . May 2017 . de . Bayer (Schweiz) AG . Zürich . compendium.ch . 15 January 2022 . https://web.archive.org/web/20190529041314/https://compendium.ch/FrmMainMonographie.aspx?Id=4a7e55ac-b11f-4d80-96d0-b468ab0eb4e3&lang=de&MonType=fi&start=1 . 29 May 2019 . dead.
  2. Web site: Gynodian® Depot . https://web.archive.org/web/20190508150613/http://www.meppo.com/pdf/drugs/859-GYNODIAN-DEPOT-1440663828.pdf . 8 May 2019 . Bayer Middle East . HCP MEPPO (Modern Medicine) .
  3. Web site: Gynodian Depot . cs . Berlin . Bayer Pharma AG . 31 October 2011 . www.sukl.cz . 15 January 2022 . https://web.archive.org/web/20190529041214/http://www.sukl.cz/download/pil/PI23959.pdf . 29 May 2019 . dead.
  4. Picha E, Weghaupt K . [Experience with a new hormone combination for menopausal disorders] . de . Medizinische Klinik . 67 . 11 . 382–386 . March 1972 . 4259772 . Experience with a new hormone combination for menopausal disorders . A new hormone combination for menopausal complaints. Since the treatment of menopausal complaints with estrogens as well as with the combination of estrogens and androgens causes undesired side effects such as bleeding, mammary changes and masculinisation, dehydroepiandrosteron (DHEA), a precursor of testosteron, has been synthesised, which has only a low conversion rate to free testosteron and no masculinising effect. The substance has been tested in combination with estrogen (200 mg DHEA-enanthate and 4 mg estradiolvalerianate per 1 ml) in 266 women with menopausal complaints. The duration of treatment has been up to 6 years with an injection interval of 3 to 8 weeks. The therapeutic results were as good as with estrogen-androgen-combinations, but there was no masculinising effect. Changes of voice, hair and libido caused by pretreatment partly disappeared. Side effects [such] as acne, mastodynia, and sensation of repletion were of transitory nature. This preparation seems to be a true alternative to the traditional estrogen-androgen-combinations. .
  5. Lauritzen C . . Experience of treatment of climacteric symptoms with depot injections of estradiol valerianate-dehydroandrosterone enantate . Die Therapiewoche . 1980 . 30 . 10 . 1736–1742 . 0040-5973 . https://www.researchgate.net/publication/322473099_Experience_of_treatment_of_climacteric_symptoms_with_depot_injections_of_estradiol_valerianate-dehydroandrosterone_oenantate -->. A trial of estradiol valerianate-dehydroandrosterone oenantate (Gynodian-Depot) was conducted in 68 post-menopausal women. The treatment exerted a very favorable influence on the typical subjective disorders of the climacteric and on the atrophic alterations of the target organs. Owing to its estrogenic and dehydroepiandrosterone components, the compound also exerts a favorable psychotropic effect. It was tolerated well and caused no side effects of any significance..
  6. Jurczok F . [Treatment of the climacteric symptom complex with a new combined hormone preparation] . de . Fortschritte der Medizin . 94 . 9 . 524–527 . March 1976 . 134967 . Treatment of the climacteric symptom complex with a new combined hormone preparation .
  7. Dinulović D, Radonjić G . [Gynodian-depot in the treatment of castration-induced postmenopause] . hr . Jugoslavenska Ginekologija I Perinatologija . 27 . 1–2 . 37–40 . 1987 . 2960859 . Gynodian-depot in the treatment of castration-induced postmenopause .
  8. Düsterberg B, Wendt H . Plasma levels of dehydroepiandrosterone and 17 beta-estradiol after intramuscular administration of Gynodian-Depot in 3 women . Hormone Research . 17 . 2 . 84–89 . 1983 . 6220949 . 10.1159/000179680 .
  9. Book: Ufer J . Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis . Hormone Therapy in Gynecology: Principles and Practice . 5th . de . 1 January 1978 . 978-3-11-006664-7 . 924728827 . de Gruyter . 276.
  10. Web site: Prasterone (Dehydroepiandrosterone, DHEA) vaginal Uses, Side Effects & Warnings.
  11. Book: Sweetman SC . Sex hormones and their modulators . Martindale: The Complete Drug Reference . 36th . 2009 . 2100, 2124–2125 . Pharmaceutical Press . London . 978-0-85369-840-1.
  12. Web site: Home . micromedexsolutions.com.
  13. Book: Muller MF, Dessing RP . European Drug Index: European Drug Registrations . Fourth. 19 June 1998. CRC Press. 978-3-7692-2114-5. 566–567.
  14. Book: Sauer F . Erfolgsfaktoren für das marktorientierte Management patentgeschützter Arzneimittel: eine Analyse der Produktwahrnehmung niedergelassener Vertragsärzte unter der Berücksichtigung unsicherer Therapieergebnisse. February 2008. BoD – Books on Demand. 978-3-936863-12-3. 37,346.
  15. Book: Kaufmann M, Costa SD, Scharl A . Die Gynäkologie. 27 November 2013. Springer-Verlag. 978-3-662-11496-4. 917–.
  16. Book: Kleemann A, Engel J, Kutscher B, Reichert D . Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. 14 May 2014. Thieme. 978-3-13-179525-0. 1172–1174, 2441–2442.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Estradiol valerate/prasterone enanthate".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.